skip to Main Content

  »  Publications


Petranova, Tzvetanka; Sheytanov, Ivan; MONOV a, S; NESTOROVAb, R; Rashkov, Rasho

Publication Year


Abstract Note

Postmenopausal osteoporosis (PMO) is a bone disease characterised by increased risk of fracture dictated by decreased bone mass, impaired bone microarchitecture and compromised bone strength. The treatment goal is to restore the balance between bone formation and degradation, to increase bone mass and reduce fracture risk. Denosumab is a therapeutic agent, fully human monoclonal antibody, targeting the receptor activator of nuclearfactor-κB ligand (RANKL), thus altering the formation, function, and survival of osteoclasts. The present paper reports data from 36 months of clinical experience with denosumab (60 mg) used for treatment of 71 women with PMO, administered subcutaneously once per 6 months. As main parameters, bone mineral density (BMD) of lumbar spine and total hip as well as trabecular bone score (TBS), were measured at baseline, months 12, 24 and 36. Results showed continuous improvement in BMD and TBS as follows: lumbar spine BMD increased with 8.9% from baseline to month 36 (0.827 at initiation vs.0.901 at month 36), total hip with 5.6% (0.673 at initiation vs.0.711 at month 36), and TBS – 4.3% (1.237 at initiation vs. 1.290 at month 36). Denosumab demonstrated valuable therapeutic profile ensuring its stable position as a first-choice treatment for PMO.


Journal of the Balkan Tribological Association





Pubmed Link

Back To Top